Dr. Levine on Immunotherapy for Endometrial Cancer

Douglas A. Levine, MD
Published: Tuesday, Sep 19, 2017



Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Immunotherapy has capitalized on what was already known regarding endometrial cancer, states Levine.

Some microsatellite instability-high tumors are inherited through a defect in mismatch-repair genes, which is important for genetic screening. There is another link between inherited genetic events that are leading to effective treatments, states Levine.
 
SELECTED
LANGUAGE


Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Immunotherapy has capitalized on what was already known regarding endometrial cancer, states Levine.

Some microsatellite instability-high tumors are inherited through a defect in mismatch-repair genes, which is important for genetic screening. There is another link between inherited genetic events that are leading to effective treatments, states Levine.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x